stockrowScilex Holding Company
SCLXHealthcare Drug Manufacturers General
Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024.
- Revenue
- −22.8%
- EPS
- −124.4%
- Free cash flow
- −203.8%
- Total debt
- +102.7%
Quarter to June 2026, against a year earlier
Follow SCLX
Alert me
Scilex Holding Company (SCLX) Return on invested capital
Scilex Holding Company's return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −92.9% (fiscal 2022) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is below the Drug Manufacturers General industry median of 6.26% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 92.93 |
| FY2022 | −92.9% | (92.93) |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2020 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| GSK GSK PLC Sponsored ADR compare | 9.61% |
| OGN Organon & Co. compare | 6.26% |
| GRFS Grifols, S.A. compare | 4.76% |
| BIIB Biogen Inc. compare | 1.94% |
| NSRX Nasus Pharma Ltd. compare | 0.00% |
| SCLX Scilex Holding Company | 0.00% |
| AMRN Amarin Corporation PLC compare | −16.6% |
| MDCX Medicus Pharma Ltd compare | −2,497.5% |
| MIRA MIRA Pharmaceuticals, Inc. compare | −12,016.1% |
| Drug Manufacturers General industry median | 6.26% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)